Core Insights - The company reported a revenue of 9.769 billion yuan for the first half of 2025, reflecting a year-on-year growth of 0.06% [1] - The net profit attributable to shareholders decreased by 7.39% to 945 million yuan, while the net profit excluding non-recurring items fell by 5.03% [1] Business Overview - The company's main business involves the production and sales of traditional Chinese medicine (TCM), with a complete industry chain that includes TCM material planting, processing, research and development, logistics distribution, and wholesale and retail [1] - The company produces over 400 varieties of TCM, with a diverse range of product forms covering various medical categories such as internal medicine, surgery, gynecology, and pediatrics [1] - Notable products include An Gong Niu Huang Wan, Tong Ren Niu Huang Qing Xin Wan, Tong Ren Da Huo Luo Wan, Liu Wei Di Huang Wan, and Jin Kui Shen Qi Wan, which are well-known both domestically and internationally [1]
同仁堂:2025年上半年归属股东净利润9.45亿元,同比下降7.39%丨财面儿